|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM332396606 |
| 003 |
DE-627 |
| 005 |
20231225215505.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202106010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1107.xml
|
| 035 |
|
|
|a (DE-627)NLM332396606
|
| 035 |
|
|
|a (NLM)34699627
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Man
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tumor-Microenvironment-Activated Reactive Oxygen Species Amplifier for Enzymatic Cascade Cancer Starvation/Chemodynamic /Immunotherapy
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2022
|
| 500 |
|
|
|a Date Revised 01.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a At present, some progress has been made in the field of cancer theranostics based on nanocatalysts (NCs), but achieving precise theranostics in response to the specific tumor microenvironment (TME) remains a major challenge. Herein, a TME-responsive upconversion nanoparticles (UCNPs)-based smart UCNPsCu-Cys-GOx (UCCG) nanosystem is engineered, which combines natural enzymes and nanozymes so as to amplify reactive oxygen species (ROS) generation in situ for cancer starvation/chemodynamic/immunotherapy. One of the biggest merits of this material is that it can be preserved inert (off) in normal tissues, and only in the TME can it be specifically activated (on) through a series of enzymatic cascades to boost ROS production via a strategy of open source (H2 O2 self-supplying ability) and reduce expenditure (glutathione (GSH) consuming ability). More importantly, the enhanced oxidative stress by UCCG NCs reverses the immunosuppressive TME, and facilitates antitumor immune responses. Meanwhile, the starvation/chemodynamic synergistic therapy triggered by UCCG combined with PD-L1 antibody effectively inhibits the growth of primary tumors and cancer metastasis. In addition, the UCNPs in UCCG present upconversion luminescence enhancement, which can be exploited to visualize the reinforced ROS generation in real time. Collectively, this work provides an original method for the devising and exploitation of UCNPs-based catalytic immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a ROS amplifiers
|
| 650 |
|
4 |
|a enzymatic cascade reactions
|
| 650 |
|
4 |
|a immune system activation
|
| 650 |
|
4 |
|a synergistic therapy
|
| 650 |
|
4 |
|a upconversion luminescence
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 700 |
1 |
|
|a Chang, Mengyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Chunxia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Qing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hou, Zhiyao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xing, Bengang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Jun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 4 vom: 01. Jan., Seite e2106010
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:4
|g day:01
|g month:01
|g pages:e2106010
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202106010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 4
|b 01
|c 01
|h e2106010
|